Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
2010 · Clinical Pharmacology & Therapeutics · 792 citations
https://doi.org/10.1038/clpt.2010.12
T
Thijs H. Oude Munnink
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
87
Papers
2.4K
Citations
19
h-index
26
i10-index
Thijs H. Oude Munnink is an academic researcher from University Medical Center Groningen. The author has contributed to research in topics: Radiopharmaceutical Chemistry and Applications & HER2/EGFR in Cancer Research & Monoclonal and Polyclonal Antibodies Research. The author has an h-index of 19, co-authored 74 publications.
ORCID: 0000-0001-8392-5858Papers by this author
worksCXCR4 Inhibition with AMD3100 Sensitizes Prostate Cancer to Docetaxel Chemotherapy
2012 · Neoplasia · 185 citations
https://doi.org/10.1593/neo.12324
89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft
2009 · European Journal of Cancer · 98 citations
https://doi.org/10.1016/j.ejca.2009.12.009
Molecular imaging of breast cancer
2009 · The Breast · 97 citations
https://doi.org/10.1016/s0960-9776(09)70276-0
Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review
2023 · Clinical Pharmacokinetics · 60 citations
https://doi.org/10.1007/s40262-023-01225-7
<sup>111</sup>In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
2014 · Molecular Imaging · 47 citations
https://doi.org/10.2310/7290.2014.00011
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat